Source: International Congress 2014 – Acute pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Noel-Savina, O. Sanchez, R. Descourt, M. Andre, G. Meyer, C. Leroyer, F. Couturaud (Brest, Paris, France). Tinzaparin and vitamin K antagonist (VKA) use in patients with cancer associated venous thromboembolism (VTE): A cohort study. Eur Respir J 2014; 44: Suppl. 58, 2404

Member's Comments

No comment yet.

Related content which might interest you: Rivaroxaban for treatment of venous thromboembolism. A real-life perspective in 103 patients Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 The diagnosis of malignancy following a venous thromboembolic event - how high is the risk? Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Treatment of venous thromboembolism in cancer patients with tinzaparin beyond 6 months. TiCAT study Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) Trial Source: Eur Respir J, 56 (4) 2000663; 10.1183/13993003.00663-2020 Year: 2020 Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Is serum cystatin C a predictor of acute pulmonary thromboembolism in patients with normal renal function? Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Occult cancer in patients with acute venous thromboembolism: Why, when and where to investigate Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Combination of sPESI and cardiac troponin in the outpatient treatment of pulmoner thromboembolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Incidence of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) at six months of a Pulmonary Embolism (PE). OSIRIS Study Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). Source: International Congress 2017 – PAH and CTEPH Year: 2017 Prognosis factors of recurrent pulmonary thromboembolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Does Wells score documentation really prevent excessive CTPA requests in a teaching hospital? A retrospective study in 800 patients Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Warfarin-associated intracranial hemorrhage during anticoagulation therapy Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Venous thromboembolic disease (VTD) associated with inflammatory bowel disease (IBD): RIETE´s experience Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 An overview of thrombolytic treatment for pulmonary embolism: A single center experience Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014